NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Neuraxis, Inc. authorized and declared a third-quarter 2026 stock dividend on its Series B Preferred Stock, payable in shares of Common Stock. Approximately 81,339 Common Stock shares are expected to be issued. Each holder’s share amount will be based on accrued and unpaid Series B dividends from July 1, 2026 through the record date, divided by $2.38.
The dividend is payable on October 30, 2026 to Series B holders of record at the close of business on October 26, 2026. No fractional Common Stock shares will be issued; holders otherwise entitled to a fraction will receive cash, without interest or deduction, equal to $2.38 multiplied by the fraction of one Series B Preferred Stock share they own.
Neuraxis, Inc. Chief Executive Officer and director Brian Allen Carrico reported a direct purchase of 268 shares of common stock on October 8, 2026, at $4.84 per share. His reported direct holdings after the transaction were 227,604 shares. The transaction is described as a purchase in the open market or a private transaction. No Rule 10b5-1 plan is reported.
Neuraxis, Inc. (NRXS) reported that Thomas Joeseph Carrico, its CRO, CCO and CPO, purchased 328 shares of common stock directly on October 8, 2026, at $4.84 per share. The transaction description lists a purchase in the open market or a private transaction. Afterward, Carrico held 199,673 shares directly. No Rule 10b5-1 plan is reported.
Neuraxis Chief Financial Officer Timothy Robert Henrichs purchased 1,937 shares of common stock at $4.84 per share on October 8, 2026. His reported direct holdings following the purchase were 9,530 shares. No Rule 10b5-1 plan is reported.
Neuraxis, INC (NRXS) reported insider equity compensation activity for officer Thomas Joeseph Carrico on 2026-08-24. Stock options for 306,236 shares were canceled and converted into an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, following approval by the board and stockholders. These RSUs vested immediately upon grant.
In a related event, 306,236 RSUs were granted and vested, and the company stated that, in connection with this vesting, 112,558 shares were withheld to satisfy income tax withholding and remittance obligations. After these events, 193,678 shares of common stock were acquired for the reporting person, bringing his directly held common stock position to 199,345 shares.
Neuraxis, Inc. (NRXS) reported that officer Adrian Miranda, CMO and SVP Science & Tech, had existing stock options canceled and replaced with restricted stock units under the company’s 2022 Omnibus Securities and Incentive Plan. 337,204 stock options were canceled in exchange for 337,204 RSUs, which vested immediately upon grant and converted into common stock. In connection with this vesting, 138,098 shares were withheld by Neuraxis to satisfy income tax obligations, and 199,106 common shares were issued and are now held directly by Miranda.
Neuraxis, INC (NRXS) reported equity compensation changes for Chief Executive Officer Brian Allen Carrico. On 2026-08-24, 320,000 stock options previously issued under a prior plan were canceled and converted into an equivalent 320,000 RSUs under the 2022 Omnibus Plan, with the RSUs vesting immediately upon grant. In connection with vesting, 120,812 shares of common stock were withheld to satisfy income tax obligations, and the remaining 199,188 shares were issued, bringing Carrico’s directly held common stock to 227,336 shares. These transactions were not reported as occurring under a Rule 10b5-1 trading plan.
Neuraxis, Inc. (NRXS) reports that a previously approved Stock Option Exchange became effective on July 24, 2026. Stockholders had approved cancelling 1,319,394 outstanding stock options under a prior plan and issuing an equivalent number of restricted stock units (RSUs) under the 2022 Omnibus Securities and Incentive Plan on a one-for-one basis. As a result, CEO Brian Carrico, CMO Adrian Miranda, and Chief Regulatory Officer Thomas Carrico received 199,188, 199,106, and 193,678 RSUs, all vesting immediately.
On August 13, 2026, after Compensation Committee approval, Neuraxis granted additional RSUs under the 2022 Plan: 193,329 to Brian Carrico, 141,479 to CFO Timothy Henrichs, 133,341 to Adrian Miranda, and 135,906 to Thomas Carrico, vesting in three equal annual installments over three years. The Compensation Committee also approved one-time equity awards totaling 127,120 shares of common stock to independent directors in recognition of prior Board service, following a review by an independent compensation consultant that found historical director compensation below market levels.
Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported that director Bradley Mitchell Watkins received an equity compensation grant of 26,073 shares of common stock on 2026-08-13. The shares were issued as compensation for services as an independent director, not as an open-market purchase, bringing his directly held stake to 72,408 shares.